Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Fortune Brands Innovations heads into its October 27 earnings report with short interest still elevated, the analyst community cutting targets in unison, and the stock down nearly 9% over the past month despite a brief bounce this week.
The positioning story is one of creeping pressure rather than acute squeeze risk. Short interest has climbed 25% over the past month, reaching 6.5% of the free float, though it eased slightly this week by about 3%. Borrowing conditions remain easy: the cost to borrow is just 0.47%, and availability has actually loosened sharply, jumping 33% on the week to 818% of short interest, meaning roughly eight shares sit available for every one already lent. With lending conditions this loose and the ORTEX short score drifting down from 52.7 on September 24 to 45.6 now, the setup looks more like a reset after a burst of bearish conviction than an active squeeze candidate. Options traders, meanwhile, are not pressing the case hard in either direction. The put/call ratio is 0.57, essentially in line with its 20-day average of 0.59, producing a z-score close to zero. The 52-week PCR range runs from 0.03 to 1.10, putting current positioning squarely in the middle of the historical spectrum.
The analyst community delivered a cluster of negative revisions this week, and the direction is uniform. RBC Capital's Mike Dahl, who raised his target to $57 after the August quarter, cut it back to $49 on October 7 while keeping his Outperform rating. Barclays trimmed to $47 from $54 the day before. Melius Research initiated fresh coverage at Hold with a $44 target, a rare day-one cautious stance that signals limited enthusiasm for a near-term re-rating. Evercore ISI had already cut to $45 from $56 in late September. The consensus mean price target is $55.80, which implies roughly 42% upside to the current price of $39.35, but that figure is being pulled down week by week as revisions accumulate. Bulls, per Benzinga's case summary, point to Moen and House of Rohl taking share in the water category, cost savings expected to reach $70 million, and a valuation in the low-to-mid teens that sits well below the historical average near 18x earnings. Bears cite management's own lowered guidance: net sales down low single digits for full-year 2026, EPS of $3.00 to $3.30, and free cash flow of $350 to $400 million. Water revenue fell 0.3% and Outdoors fell 3.4% in the most recent quarter. The PE multiple is near 11.7x, down nearly a full turn over the past month, reflecting the market's recalibration.
One ownership data point stands out. Pictet Asset Management filed an amended Schedule 13D in August, the activist designation on the register, reducing its stake from 5.3% to 4.9%. A 13D filer trimming below 5% is notable because that holder may never file again; the position is as last disclosed and could be smaller now. That said, Greenlight Capital appeared fresh in the June 30 institutional data with a new stake of 1.88%, and Dimensional Fund Advisors added 526,000 shares. On the insider side, CEO Jesse Singh made three open-market purchases in early August, paying around $50 to $52 per share for a combined outlay close to $2 million, none under a 10b5-1 plan. Those buys now sit roughly 23% underwater at the current price of $39.35, and the stock has not recovered that ground.
The earnings history adds a nuanced backdrop. The last two reported prints both produced near-flat next-day moves, with a 5-day drift lower of around 4% following the most recent August result. The October 27 print will land against a backdrop where management has already reset full-year expectations lower, so the question on the day will be less about whether numbers are weak and more about whether the revised guidance range proves achievable in the face of continued pressure on new construction and repair-and-remodel activity.
The EV/EBITDA sits near 9x, up modestly over the past month. The price-to-book is 1.85, down about 7% over the same period. Factor rankings on EPS momentum are weak, 12 on the 30-day measure and 19 on the 90-day, though the 12-month forward earnings growth score ranks in the 70th percentile, suggesting the Street is looking past near-term pain. With availability loose, borrowing cheap, the short score edging lower, and a three-week runway to the print, the key variable is whether the analyst target-cutting cycle has run its course or whether October 27 brings another round.
See the live data behind this article on ORTEX.
Open FBIN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
